R7128: Phase I ongoing

Pharmasset began dosing of the third and fourth 25-patient cohorts in a single-blind, placebo-controlled Phase I trial evaluating oral R7128 plus Pegasys peginterferon alfa-2a and Copegus ribavirin ...